Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527353 | 0.86 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL16667943 | 0.81 | FGFR4 (0.45) | NPC1RAB9ACHEK1FGFR4PLK1 | |
| SCHEMBL16670562 | 0.80 | FGFR4 (0.44) | KDM4CMEN1KMT2AFGFR4 | |
| SCHEMBL24517704 | 0.77 | KDM4C (0.47) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL29703962 | 0.77 | KDM4C (0.47) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL24517880 | 0.77 | KDM4C (0.47) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL29703954 | 0.77 | KDM4C (0.47) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL16668846 | 0.77 | FGFR4 (0.44) | CHEK1FGFR4PLK1 | |
| SCHEMBL16667979 | 0.76 | FGFR4 (0.42) | CHEK1FGFR4PLK1PIK3CA | |
| SCHEMBL16667807 | 0.75 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060563-B1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9896449-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-03-09 | — | — | US | disclosed |
| US-9533988-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-9266883-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2015-04-30 | — | — | US | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119385-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | KDM4C 238/4885L3MBTL1 4811/4885NPC1 2100/4885 |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | KDM4C 238/4885L3MBTL1 4811/4885NPC1 2100/4885 |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | KDM4C 238/4885L3MBTL1 4811/4885NPC1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.